Cell-based platform for safe tumor treatments

Our proprietary platform centers on a transgene expression control vector that provides dual control at the transcriptional and post-transcriptional level. Together these ensure therapeutics are released within the tumor and limit systemic toxicity.

A Tie-2 promoter ensures the transgene transcription occurs in TEMs, while miRNA-126 target sequences inhibit expression of the transgene in hematopoietic stem and progenitor cells.